Nama's AI scorecard currently rates CONMED Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is CNMD's P/E ratio?

CONMED trades at a trailing price-to-earnings ratio of 10.9.

When does CNMD report earnings?

CONMED's next scheduled report is on Jan 27, 2027. Analysts expect EPS of $1.26.

What is the CNMD price target?

The median analyst price target from 6 analysts is $47.00, with a range of $43.00 – $50.00.

Is CNMD Shariah compliant?

Nama's AAOIFI-style screen reads CONMED as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does CNMD pay a dividend?

Yes — CONMED's dividend yield is 1.6%.

Nama Insights

CONMED (CNMD)

Healthcare · Medical Devices · NYSE

CONMED (CNMD) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.53B, a trailing price-to-earnings ratio of 10.9 and a free-cash-flow yield of 9.4%. Over the most recent reported fiscal year, revenue grew 5.2% and free cash flow per share fell 1.9%. Nama's AI scorecard rates it Hold, 4.8 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 4.8/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · +0.0% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-67.5%

How far the last close sits under the highest price of the past five years.

Market cap	$1.53B
Trailing P/E	10.9
Price / book	1.5
Price / sales	1.1
FCF yield	9.4%
Dividend yield	1.6%
Gross margin	55.8%
Operating margin	8.0%
Net margin	4.1%
Revenue growth (YoY)	+5.2%
Revenue growth (3-yr annual)	+9.6%
EPS growth (YoY)	+10.8%
FCF/share growth (YoY)	-1.9%
Beta	0.9
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

CNMD earnings

Next report: Jan 27, 2027 (Q4 2026, EPS estimate $1.26). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 28, 2026	$1.04	$1.00	+4.0%	$335.56M
Q2 2026	Jul 29, 2026	$1.38	$1.11	+24.3%	$343.49M
Q1 2026	Apr 29, 2026	$0.89	$0.82	+8.5%	$317.05M
Q4 2025	Jan 28, 2026	$1.43	$1.32	+8.3%	$373.20M

CNMD analyst price target

Median target $47.00 from 6 analysts, ranging $43.00 – $50.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live CNMD data on Nama Insights →

CNMD FAQ

Is CNMD a buy?: Nama's AI scorecard currently rates CONMED Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CNMD's P/E ratio?: CONMED trades at a trailing price-to-earnings ratio of 10.9.
When does CNMD report earnings?: CONMED's next scheduled report is on Jan 27, 2027. Analysts expect EPS of $1.26.
What is the CNMD price target?: The median analyst price target from 6 analysts is $47.00, with a range of $43.00 – $50.00.
Is CNMD Shariah compliant?: Nama's AAOIFI-style screen reads CONMED as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does CNMD pay a dividend?: Yes — CONMED's dividend yield is 1.6%.